Anti-Cancer Agent, Herceptin Obtained Approval for Dosage and Administration for Postoperative Adjuvant Chemotherapy in Breast Cancer in Japan
Please find attached a press release by Chugai (Source: Roche Investor Update)
Source: Roche Investor Update - June 14, 2013 Category: Pharmaceuticals Source Type: news

How Do We Know Which Cancer Therapies Really Work?
The FDA has approved more than 30 molecularly targeted agents in cancer in recent years, including prominent examples such as trastuzumab for breast cancer, sunitinib for renal cell cancer and bevacizumab for colorectal, non-small cell lung and renal cell cancers.06/13/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 13, 2013 Category: Cancer & Oncology Source Type: news

Herceptin - A Targeted Biologic Therapy for...
Read a description of Herceptin (trastuzumab), how it works, about the side effects, and get some self-care tips. Herceptin is given for HER2 positive breast cancer as a targeted biologic therapy. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - June 5, 2013 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

ASCO: Afinitor Quells Herceptin Resistance
CHICAGO (MedPage Today) -- A study presented here may help unravel the issue of resistance to trastuzumab (Herceptin), a drug that is central to the treatment of HER2-positive breast cancer. (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - June 4, 2013 Category: OBGYN Source Type: news

HERA Trial: Invasive Lobular Breast Carcinoma Patients Derived Same Benefit From Trastuzumab Maintenance
In the HERA trial, benefit for invasive lobular breast cancer patients with 1 year of trastuzumab maintenance was similar to invasive ductal carcinoma patients. (Source: Cancer Network)
Source: Cancer Network - May 7, 2013 Category: Cancer & Oncology Source Type: news

FDA Warns of Name Confusion for 2 Breast Cancer DrugsFDA Warns of Name Confusion for 2 Breast Cancer Drugs
The use of a truncated version of the generic name for Kadcyla (ado-trastuzumab emtansine) invites a potentially harmful mix-up with Herceptin (trastuzumab), the FDA has warned. News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 7, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Kadcyla (ado-trastuzumab emtansine): Drug Safety Communication - Potential Medication Errors Resulting from Name Confusion
Use of the incorrect nonproprietary name for Kadcyla in some medication-related electronic systems poses a risk of mix-up with Herceptin (trastuzumab). (Source: FDA MedWatch)
Source: FDA MedWatch - May 6, 2013 Category: American Health Source Type: news

PIK3CA Mutations Negatively Affect Survival in Trastuzumab-Treated HER2-Positive Breast Cancer
A study confirmed that PIK3CA mutations negatively affect survival in patients with HER2-positive breast cancer treated with the anti-HER2 therapy trastuzumab. (Source: Cancer Network)
Source: Cancer Network - May 6, 2013 Category: Cancer & Oncology Source Type: news

Everolimus Can Overcome Trastuzumab Resistance In HER-2 Positive Early Breast Cancer
A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle. The study showed a statistically non-significant benefit in clinical response rates for some patients with early breast cancer when everolimus was added to treatment with trastuzumab. Yet the results suggest this benefit is achieved independently of the molecular pathways researchers expected would be involved... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 6, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

New DNA Blood Test Could Increase Access To Herceptin
A new blood test for women with breast cancer could identify more women who will benefit from the targeted treatment Herceptin without the need for uncomfortable biopsies. The new 'liquid biopsy' uses cutting-edge genetic techniques to detect breast cancer DNA in the bloodstream, and was developed by a team at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 2, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer
(European Society for Medical Oncology) A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab showed a statistically non-significant benefit in clinical response rates when everolimus is added to trastuzumab. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 2, 2013 Category: Cancer & Oncology Source Type: news

Patients With Lung Cancer Who Carry Specific HER2 Mutations May Benefit From Certain Anti-HER2 Treatments
New results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent trastuzumab (Herceptin), have anti-cancer effects in a small subset of patients with advanced non-small cell lung cancer (NSCLC) harboring specific HER2 protein mutations. Although genetic changes cause tumor cells to make too much of the HER2 protein in up to 20% of lung cancers, mutations in the HER2 gene occur in only 1-2% of lung cancers... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 24, 2013 Category: Consumer Health News Tags: Lung Cancer Source Type: news

HER2-Targeted Drugs Useful in Some Lung Cancer PatientsHER2-Targeted Drugs Useful in Some Lung Cancer Patients
Drugs such as trastuzumab have already transformed the treatment of breast cancer. New research suggests they may also be useful in lung cancer. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 23, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Trastuzumab-Induced Cardiotoxicity in Early Breast CancerTrastuzumab-Induced Cardiotoxicity in Early Breast Cancer
How frequently does trastuzumab-induced cardiotoxicity occur? Heart (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 22, 2013 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Breast cancer drug receives 'breakthrough therapy' designation from FDA
An experimental drug being investigated for the treatment of advanced breast cancer by researchers from the Revlon/UCLA Women's Cancer Research Program at UCLA's Jonsson Comprehensive Cancer Center this week received "breakthrough therapy" designation from the U.S. Food and Drug Administration.   In a clinical trial, patients with advanced breast cancer that was estrogen-receptor positive (ER+) and HER2-negative (HER2-), and who were given palbociclib (PD 0332991, Pfizer Inc.) in addition to the standard anti-estrogen treatment of letrozole had significantly higher progression-free survival — the lengt...
Source: UCLA Newsroom: Health Sciences - April 12, 2013 Category: Universities & Medical Training Source Type: news

AACR: Targeting Luminal Breast Cancer Stem Cells With Trastuzumab Blocks Metastatic Growth in Preclinical Models
Trastuzumab (Herceptin) therapy may be useful for the treatment of luminal breast cancer stem cells, preventing them from growing into macrometastases, according to preclinical results presented at the 2013 American Association for Cancer Research Annual Meeting. (Source: Cancer Network)
Source: Cancer Network - April 9, 2013 Category: Cancer & Oncology Source Type: news

T-DM1 and the Dawn of Precision MedicineT-DM1 and the Dawn of Precision Medicine
Dr. Maurie Markman sees T-DM1, which combines antitumor activities of trastuzumab and HER2-targeted delivery of a cytotoxic agent, as an example of the precision medicine we can expect in the future. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 20, 2013 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

HER2-Positive Breast Cancer Patients Prefer Faster Subcutaneous Administration Of Herceptin® (Trastuzumab) To IV
Further research also reveals quicker administration of Herceptin could save NHS £15m compared to current practice1 Results from the PrefHer (Patient Preference for Subcutaneous (SC) versus Intravenous (IV) Herceptin) trial show that 92% of early HER2-positive breast cancer patients favoured quicker SC administration of Herceptin compared to the standard IV infusion.1 Presented at the St. Gallen Breast Cancer Conference in Switzerland. The primary reasons for preferring SC administration given by patients in the trial were less pain/discomfort and time saving... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 19, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

New Treatment For Advanced HER2+ Breast Cancer Patients As Perjeta® (Pertuzumab) Gets Regulatory Green Light
Perjeta works synergistically with Herceptin® (trastuzumab) to extend survival and stall disease progression for longer than the gold standard of care[i] From now on, patients with advanced HER2-positive breast cancer could benefit from the new personalised breast cancer treatment, Perjeta - which is now authorised for use in the UK. Perjeta has been granted a licence by the European Medicines Agency (EMA), for patients with previously untreated advanced HER2-positive breast cancer in combination with the current gold standard-of-care, Herceptin and chemotherapy (docetaxel)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 19, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Trastuzumab for Breast Cancer Linked to CNS MetastasesTrastuzumab for Breast Cancer Linked to CNS Metastases
An analysis of 4 RCTs has shown an association between adjuvant trastuzumab for breast cancer and the development of central nervous system (CNS) metastases as the site of first recurrence. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 14, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Breast cancer drug 'biggest boost since Herceptin'
Thousands of women with a type of advanced breast cancer could benefit from a drug described as the biggest step-change in treatment of the disease since Herceptin was introduced in 1999. (Source: Telegraph Health)
Source: Telegraph Health - March 14, 2013 Category: Consumer Health News Tags: perjeta herceptin tumour roche breast cancer HER2 Source Type: news

Editorial: Trastuzumab induced cardiomyopathy-wider implications for cardio-oncology
Source: Heart Area: News This editorial in 'Heart' notes the twofold rise in incidence of breast cancer over the past 20 years and that treatments have become significantly more effective and mortality has fallen by 50% over the last 30 years, though this has required more aggressive treatment regimens. The authors discuss anthracyclines, HER-2, anthracyclines plus trastuzumab and recent clinical studies, and note a number of unresolved issues:   (1) How big a problem is chemotherapy cardiomyopathy in routine clinical practice (2) Do we have effective means of early diagnosis? (3) Are there effective pharmace...
Source: NeLM - Cardiovascular Medicine - March 14, 2013 Category: Cardiology Source Type: news

Roche obtains EU approval for PERJETA, a new personalised treatment for aggressive type of breast cancer
Roche today announced that the European Medicines Agency (EMA) has approved PERJETA(pertuzumab) for patients with previously untreated HER2-positive metastatic breast cancer (mBC). PERJETA is approved in combination with Herceptin (trastuzumab) and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. (Source: Roche Investor Update)
Source: Roche Investor Update - March 5, 2013 Category: Pharmaceuticals Source Type: news

Efficacy, Not Price, of New Breast Cancer Drug Is WelcomedEfficacy, Not Price, of New Breast Cancer Drug Is Welcomed
Trastuzumab emtansine, also known as T-DM1, is effective but expensive. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 1, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Research and Markets Announces Addition of the "Risk - Reward of...
This report discusses multiple aspects to the market for Herceptin biosimilars including technologies being incorporated, competitor activity and much more.(PRWeb February 28, 2013)Read the full story at http://www.prweb.com/releases/2013/2/prweb10478514.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 28, 2013 Category: Pharmaceuticals Source Type: news

Breast Cancer Stem Cells Express HER2, Even In 'Negative' Tumors, Study Finds
New research from the University of Michigan Comprehensive Cancer Center finds that the protein HER2 plays a role even in breast cancers that would traditionally be categorized as HER2-negative - and that the drug Herceptin, which targets HER2, may have an even greater role for treating breast cancer and preventing its spread. About 20 percent of women with breast cancer have tumors labeled HER2-positive... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 28, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

ADC: The Next Big Opportunity For Oncology Drugs
The commercial success of mAb products such as Rituxan, Erbitux, and Herceptin has catapulted mAbs to the forefront of molecular medicine. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - February 27, 2013 Category: Pharmaceuticals Source Type: news

HER2 Therapy Useful in More Than 20% of Breast CancersHER2 Therapy Useful in More Than 20% of Breast Cancers
The finding of HER2 in the small clump of cancer stems cells that drives the growth and spread of tumors suggests a wider use for drugs such as trastuzumab. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 26, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Herceptin 'could benefit thousands more women'
The highly effective breast cancer drug Herceptin could benefit thousands more women, according to a study which suggests it could stop the disease spreading in most patients if given early enough. (Source: Telegraph Health)
Source: Telegraph Health - February 26, 2013 Category: Consumer Health News Tags: herceptin michigan university cancer research breast cancer HER2 Source Type: news

Kadcyla Wins US FDA Approval for Late-Stage Breast Cancer
Ado-trastuzumab emtansine, a HER-2 targeted antibody-drug conjugate, has been approved by the U.S. Food and Drug Administration for treatment of women with HER2-positive, late-stage metastatic breast cancer,... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 26, 2013 Category: Cancer & Oncology Source Type: news

U-M study challenges notion of using Herceptin only for HER2-positive breast cancer
(University of Michigan Health System) New research from the University of Michigan Comprehensive Cancer Center finds that the protein HER2 plays a role even in breast cancers that would traditionally be categorized as HER2-negative -- and that the drug Herceptin, which targets HER2, may have an even greater role for treating breast cancer and preventing its spread. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 26, 2013 Category: Cancer & Oncology Source Type: news

Breast cancer: The liver operation that gives breast cancer patients a new lease of life
Susan Welch underwent a course of chemotherapy and Herceptin, a drug that targets certain types of breast cancer cells. (Source: the Mail online | Health)
Source: the Mail online | Health - February 26, 2013 Category: Consumer Health News Source Type: news

Horizon scanning: US FDA approves ado-trastuzumab emtansine or T-DM1 (KadcylaT) for HER2-positive metastatic breast cancer
Source: BioSpace Area: News The US FDA has approved the antibody-drug conjugate ado-trastuzumab emtansine or T-DM1 (KadcylaT) for the treatment of people with HER2-positive metastatic breast cancer who have received prior treatment with trastuzumab (Herceptin®) and a taxane.   KadcylaT, which is composed of the cytotoxic agent DM1 conjugated to trastuzumab, is the first antibody-drug conjugate to be approved by the FDA for the treatment of metastatic breast cancer. The approval was based on the results of the EMILIA Phase III study (n=991), which compared KadcylaT alone to lapatinib in combination with capec...
Source: NeLM - News - February 25, 2013 Category: Drugs & Pharmacology Source Type: news

Kadcyla Wins FDA Approval For HER2 Breast Cancer
A new drug will soon be available to treat HER2-positive metastatic breast cancer. Made by Genentech, it will be known as Kadcyla (ado-trastuzumab emtansine). This drug is a highly targeted ...Read Full Post (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - February 25, 2013 Category: Cancer & Oncology Source Type: news

FDA approves Genentech metastatic breast cancer drug
The US Food and Drug Administration (FDA) has approved Genentech's Kadcyla (ado-trastuzumab emtansine or T-DM1) for the treatment of HER2-positive metastatic breast cancer (mBC). (Source: Drug Development Technology)
Source: Drug Development Technology - February 25, 2013 Category: Pharmaceuticals Source Type: news

FDA OKs Genentech Breast Cancer Drug
(MedPage Today) -- A drug antibody conjugate called ado-trastuzumab emtansine (Kadcyla) received FDA approval Friday for HER2-positive, metastatic breast cancer. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 23, 2013 Category: Hematology Source Type: news

Local Oncologist Says Kadcyla Is “A Really Good Drug”
BOSTON (CBS) – The FDA approval of the breast cancer drug Kadcyla is getting a welcome reception from a local oncologist. WBZ’s Diane Stern spoke with Dr. Eric Weiner, Director of the Breast Oncology Center at Dana Farber Cancer Institute. Kadcyla combines the drug Herceptin, with a powerful chemotherapy drug and a third chemical. The cocktail binds to a cancer cell, delivering a double-shot of anti-tumor poison. WBZ NewsRadio’s Diane Stern reports Download: breast-cancer-web-ext.mp3 “It is a big deal,” Weiner says. “We’ve actually...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - February 23, 2013 Category: Consumer Health News Authors: deanreddington Tags: Health Heard On WBZ NewsRadio 1030 Local Syndicated Local Watch Listen Boston Breast Cancer Dr. Eric Weiner Kadcyla Source Type: news

FDA Approves Kadcyla for Late-Stage Breast Cancer
February 22, 2013 -- The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer. HER2 is a protein involved in normal cell growth.... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 22, 2013 Category: Drugs & Pharmacology Source Type: news

Kadcyla For Late-Stage Breast Cancer Approved By FDA
Kadcyla (ado-trastuzumab emtansine), a new medication for the treatment of HER2-positive, metastatic breast cancer, has been approved by the Food and Drug Administration (FDA), USA. Metastatic, also known as late-stage, means the cancer has spread to other parts of the body. HER2, a protein which drives normal cell growth, is found in larger quantities in several kinds of cancer cells (HER2-positive), including a number of breast cancers. The HER2 protein contributes to the growth and survival of cancer cells in patients with HER2-positive breast cancer... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 22, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

FDA Approves New Treatment for Metastatic HER2 Breast CancerFDA Approves New Treatment for Metastatic HER2 Breast Cancer
Trastuzumab emtansine, also known as T-DM1, provides clinicians with another treatment option for patients who progress on trastuzumab. FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 22, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

F.D.A. Approves Breast Cancer Drug
The new type of drug combines the widely used breast cancer medicine Herceptin with a powerful toxin to more effectively kill cancer cells while potentially reducing side effects. (Source: NYT Health)
Source: NYT Health - February 22, 2013 Category: Consumer Health News Authors: By ANDREW POLLACK Tags: Drugs (Pharmaceuticals) Food and Drug Administration Cancer Breast Cancer Source Type: news

FDA approves Roche's Kadcyla (trastuzumab emtansine), the first antibody-drug conjugate for treating HER2-positive metastatic breast cancer
New personalised medicine helped people in Phase III study live longer, compared to standard treatment (Source: Roche Media News)
Source: Roche Media News - February 22, 2013 Category: Pharmaceuticals Source Type: news

FDA approves Roche's Kadcyla (trastuzumab emtansine), the first antibody-drug conjugate for treating HER2-positive metastatic breast cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Kadcyla (trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin (trastuzumab) and a taxane chemotherapy. (Source: Roche Investor Update)
Source: Roche Investor Update - February 22, 2013 Category: Pharmaceuticals Source Type: news

FDA approves new treatment for late-stage breast cancer
The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer. (Source: Food and Drug Administration)
Source: Food and Drug Administration - February 22, 2013 Category: American Health Source Type: news

FDA Approves T-DM1 (Kadcyla) for HER2-Positive Breast Cancer
The US Food and Drug Administration approved ado-trastuzumab emtansine (Kadcyla) for the treatment of patients with metastatic HER2-positive breast cancer earlier today. (Source: Cancer Network)
Source: Cancer Network - February 22, 2013 Category: Cancer & Oncology Source Type: news

ImmunoGen, Inc. Announces FDA Approval Of Kadcyla (Ado-Trastuzumab Emtansine; Also Known As T-DM1)
ImmunoGen, Inc ., a biotechnology company that develops anticancer therapeutics using its TAP technology, recently announced that Roche has reported that the U.S. Food and Drug Administration (FDA) has granted marketing approval to Kadcyla for the treatment of people with HER2-positive metastatic breast cancer who have received prior treatment with Herceptin (trastuzumab) and a taxane chemotherapy. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - February 22, 2013 Category: Pharmaceuticals Source Type: news

FDA Approves Genentech's Kadcyla (Ado-Trastuzumab Emtansine), The First Antibody-Drug Conjugate For Treating HER2-Positive Metastatic Breast Cancer
Genentech, a member of the Roche Group recently announced that the U.S. Food and Drug Administration (FDA) has approved Kadcyla(ado-trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin (trastuzumab) and a taxane chemotherapy. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - February 22, 2013 Category: Pharmaceuticals Source Type: news

You Will Remember This DayYou Will Remember This Day
The FDA's approval of trastuzumab emtansine (T-DM1) for metastatic breast cancer, says Dr. Kathy Miller, marks a historic day in the fight against breast cancer. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 21, 2013 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Is Lapatinib an Option When Trastuzumab Is Not?Is Lapatinib an Option When Trastuzumab Is Not?
Globally, trastuzumab is not always available for women with HER2+ breast cancer. Dr. Lidia Schapira reports on a study that looks at the potential benefit of oral lapatinib after primary therapy. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 19, 2013 Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab (BIG 1-01)
Source: Lancet Oncology Area: News Several randomised trials have confirmed the benefit of adjuvant trastuzumab for patients with HER2-positive early breast cancer but have identified CNS as the first site of relapse, possibly because trastuzumab does not adequately penetrate the CNS. To investigate further, researchers used data from the HERA trial to assess the frequency and course of CNS relapses, either as first event or at any time.   The HERA trial (BIG 1-01) is a large randomised phase 3 study comparing treatment with adjuvant trastuzumab after standard adjuvant chemotherapy for 1 year or 2 years with only...
Source: NeLM - News - February 13, 2013 Category: Drugs & Pharmacology Source Type: news